SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Ascendis Pharma Reports Kidney Function Improvements With TransCon PTH

Ascendis Pharma said new data show sustained, clinically meaningful improvements in kidney function in adults with hypoparathyroidism treated with TransCon PTH for up to five years.

ASND

Related stories